CO6680667A2 - Derivados ester de ácido borónico cíclico y sus usos terapéuticos - Google Patents
Derivados ester de ácido borónico cíclico y sus usos terapéuticosInfo
- Publication number
- CO6680667A2 CO6680667A2 CO13037941A CO13037941A CO6680667A2 CO 6680667 A2 CO6680667 A2 CO 6680667A2 CO 13037941 A CO13037941 A CO 13037941A CO 13037941 A CO13037941 A CO 13037941A CO 6680667 A2 CO6680667 A2 CO 6680667A2
- Authority
- CO
- Colombia
- Prior art keywords
- boronic acid
- ester derivatives
- cyclic boronic
- therapeutic uses
- cyclic
- Prior art date
Links
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 title 1
- 125000004122 cyclic group Chemical group 0.000 title 1
- 150000002148 esters Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 cyclic boronic acid ester Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen aquí composiciones de compuestos antimicrobianos, composiciones farmacéuticas, su uso y preparación. La invención se refiere a derivados éster de ácido borónico cíclico de la fórmula I y su uso como agentes terapéuticos, particularmente en el tratamiento de infecciones bacterianas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37229610P | 2010-08-10 | 2010-08-10 | |
US201161488655P | 2011-05-20 | 2011-05-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6680667A2 true CO6680667A2 (es) | 2013-05-31 |
Family
ID=45565270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO13037941A CO6680667A2 (es) | 2010-08-10 | 2013-02-25 | Derivados ester de ácido borónico cíclico y sus usos terapéuticos |
Country Status (27)
Country | Link |
---|---|
US (10) | US8680136B2 (es) |
EP (3) | EP2603514B1 (es) |
JP (4) | JP6266978B2 (es) |
KR (3) | KR102205755B1 (es) |
CN (1) | CN103180328B (es) |
AU (1) | AU2011289615B2 (es) |
BR (1) | BR112013003045B1 (es) |
CA (1) | CA2807546C (es) |
CL (1) | CL2013000399A1 (es) |
CO (1) | CO6680667A2 (es) |
CY (3) | CY1123208T1 (es) |
DK (2) | DK3412676T3 (es) |
ES (2) | ES2789177T3 (es) |
HR (1) | HRP20200741T1 (es) |
HU (4) | HUE040086T2 (es) |
IL (1) | IL224564A (es) |
LT (3) | LT3412676T (es) |
MX (1) | MX348653B (es) |
MY (1) | MY188960A (es) |
NO (2) | NO2019014I1 (es) |
NZ (1) | NZ607354A (es) |
PL (2) | PL3412676T3 (es) |
PT (2) | PT3412676T (es) |
RS (1) | RS60310B1 (es) |
RU (1) | RU2599791C2 (es) |
SG (1) | SG187757A1 (es) |
WO (1) | WO2012021455A1 (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8680136B2 (en) | 2010-08-10 | 2014-03-25 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
US9012491B2 (en) * | 2011-08-31 | 2015-04-21 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
EP2814483A2 (en) * | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
US9505728B2 (en) | 2012-03-09 | 2016-11-29 | Inception 2, Inc. | Triazolone compounds and uses thereof |
US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US10561675B2 (en) * | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
WO2014052836A2 (en) | 2012-09-27 | 2014-04-03 | Dunman Paul M | Methods and compositions for treating infection |
WO2014089365A1 (en) | 2012-12-07 | 2014-06-12 | Venatorx Pharmaceuticals, Inc | Beta-lactamase inhibitors |
CN104918922B (zh) | 2012-12-20 | 2017-04-26 | 因森普深2公司 | 三唑酮化合物及其用途 |
US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
EA201591003A1 (ru) | 2013-01-04 | 2015-12-30 | Ремпекс Фармасьютикалз, Инк. | Производные бороновой кислоты и их терапевтическое применение |
US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
CN104981239B (zh) * | 2013-01-04 | 2019-01-04 | 莱姆派克斯制药公司 | 硼酸衍生物及其治疗用途 |
ES2730013T3 (es) | 2013-01-10 | 2019-11-07 | Venatorx Pharmaceuticals Inc | Inhibidores de betalactamasa |
US9944658B2 (en) | 2013-03-14 | 2018-04-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
CA3011999A1 (en) * | 2013-05-03 | 2014-11-06 | Microbiotix, Inc. | Antimicrobial potentiators |
EA201690230A1 (ru) | 2013-09-06 | 2016-07-29 | Инсепшн 2, Инк. | Соединения триазолона и их применения |
PT3140310T (pt) * | 2014-05-05 | 2019-11-18 | Rempex Pharmaceuticals Inc | Síntese de sais de boronato e utilizações dos mesmos |
US9687497B1 (en) | 2014-05-05 | 2017-06-27 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
KR20170007448A (ko) | 2014-05-19 | 2017-01-18 | 렘펙스 파머수티클스 인코퍼레이티드 | 보론산 유도체 및 그의 치료적 용도 |
US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
CN106687465B (zh) | 2014-06-11 | 2019-04-16 | 维纳拓尔斯制药公司 | β-内酰胺酶抑制剂 |
MX2016016666A (es) * | 2014-07-01 | 2017-08-08 | Rempex Pharmaceuticals Inc | Derivados de acido boronico y usos terapeuticos de los mismos. |
US10662205B2 (en) | 2014-11-18 | 2020-05-26 | Qpex Biopharma, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
CN104447610A (zh) * | 2014-11-21 | 2015-03-25 | 山东金城医药化工股份有限公司 | 高纯度头孢他啶侧链酸的制备方法 |
CN107207537B (zh) * | 2014-12-19 | 2019-05-31 | 莱姆派克斯制药公司 | 用于生产硼酸衍生物的设备和连续流方法 |
WO2016149393A1 (en) | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
CN107530364A (zh) | 2015-04-24 | 2018-01-02 | 莱姆派克斯制药公司 | 治疗细菌感染的方法 |
EP3347008B1 (en) | 2015-09-11 | 2022-03-09 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
WO2017100537A1 (en) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
ES2894251T3 (es) * | 2016-06-30 | 2022-02-14 | Qpex Biopharma Inc | Derivados de ácido borónico y usos terapéuticos de los mismos |
EP3494121B1 (en) | 2016-08-04 | 2021-10-06 | Venatorx Pharmaceuticals, Inc. | Boron-containing compounds |
EP3559009B1 (en) * | 2016-12-22 | 2021-04-07 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
CA3048650A1 (en) | 2017-01-09 | 2018-07-12 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
JOP20190188A1 (ar) | 2017-02-01 | 2019-08-01 | Rempex Pharmaceuticals Inc | جهاز وعملية تدفق مستمرة لإنتاج مشتق حمض بورونيك |
CN110678186A (zh) | 2017-03-06 | 2020-01-10 | 维纳拓尔斯制药公司 | 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途 |
US11267826B2 (en) | 2017-05-26 | 2022-03-08 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
EP3630782A4 (en) | 2017-05-26 | 2021-03-03 | Venatorx Pharmaceuticals, Inc. | PENICILLIN BINDING PROTEIN INHIBITORS |
WO2019075084A1 (en) | 2017-10-11 | 2019-04-18 | Qpex Biopharma, Inc. | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF |
JOP20200101A1 (ar) | 2017-11-01 | 2022-10-30 | Melinta Therapeutics Inc | تخليق مشتقات إستر بورونات واستخداماتها |
CN111039965B (zh) * | 2018-10-12 | 2020-12-01 | 新发药业有限公司 | 一种法硼巴坦的简便制备方法 |
WO2022182993A1 (en) * | 2021-02-25 | 2022-09-01 | Ohio State Innovation Foundation | Liposomal formulations of boronic acid containing active agents |
CN113214302B (zh) * | 2021-04-23 | 2022-06-24 | 四川大学 | 一种抑制金属β-内酰胺酶和/或丝氨酸β-内酰胺酶的3-取代五元环状硼酸酯衍生物 |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3686398A (en) | 1970-07-20 | 1972-08-22 | Chevron Res | 10,9-boroxarophenanthrene as fungicides |
US4194047A (en) | 1975-11-21 | 1980-03-18 | Merck & Co., Inc. | Substituted N-methylene derivatives of thienamycin |
US4260543A (en) | 1978-07-03 | 1981-04-07 | Merck & Co., Inc. | Crystalline N-formimidoyl thienamycin |
US4409214A (en) | 1979-11-19 | 1983-10-11 | Fujisawa Pharmaceutical, Co., Ltd. | 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof |
US4353807A (en) | 1981-03-24 | 1982-10-12 | Mobil Oil Corporation | Lubricants and fuels containing boroxarophenanthrene compounds |
FR2573070B1 (fr) | 1984-11-13 | 1987-01-30 | Rhone Poulenc Sante | Procede de preparation de composes carbonyles |
FR2574070B1 (fr) | 1984-11-30 | 1987-02-27 | Stam | Catalyseur de prise de mortiers d'anhydrite projetes a la lance, a resistance amelioree a un stockage a temperature et humidite elevees, et utilisation d'un tel catalyseur |
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
US4822786A (en) | 1986-07-01 | 1989-04-18 | Kaken Pharmaceutical Co., Ltd. | Cephalosporin compounds, and antibacterial agents |
ZA893284B (en) | 1988-05-04 | 1990-03-28 | Igen Inc | Peptide analogs and their use as haptens to elicit catalytic antibodies |
US5442100A (en) | 1992-08-14 | 1995-08-15 | The Procter & Gamble Company | β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids |
US5888998A (en) | 1997-04-24 | 1999-03-30 | Synphar Laboratories, Inc. | 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors |
US6184363B1 (en) | 1997-06-13 | 2001-02-06 | Northwestern University | Inhibitors of β-lactamases and uses therefor |
US6075014A (en) | 1997-06-13 | 2000-06-13 | Northwestern University | Inhibitors of β-lactamases and uses therefor |
AU2190400A (en) | 1998-12-16 | 2000-07-03 | Northwestern University | Inhibitors of beta-lactamases and uses therefor |
AU3124300A (en) | 1998-12-16 | 2000-07-03 | Northwestern University | Inhibitors of beta-lactamases and uses therefor |
AU765020B2 (en) | 1999-09-25 | 2003-09-04 | Smithkline Beecham Plc | Piperazine derivatives as 5-HT1B antagonists |
JP2003513890A (ja) | 1999-10-28 | 2003-04-15 | メルク エンド カムパニー インコーポレーテッド | 新規なコハク酸系メタロ−β−ラクタマーゼ阻害薬およびそれの細菌感染治療での使用 |
WO2002022137A1 (en) | 2000-09-12 | 2002-03-21 | Shoichet Brian K | β-LACTAM ANALOGS AND USES THEREFOR |
US6916803B2 (en) | 2000-09-14 | 2005-07-12 | Pantherix, Ltd. | 3-(Heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents |
US6586615B1 (en) | 2001-01-10 | 2003-07-01 | Bristol-Myers Squibb Company | α-aminoboronic acids prepared by novel synthetic methods |
DE10118698A1 (de) | 2001-04-17 | 2002-11-07 | Jerini Ag | Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche |
AU2002360732A1 (en) | 2001-12-26 | 2003-07-24 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
JP2003229277A (ja) | 2002-02-04 | 2003-08-15 | Matsushita Electric Ind Co Ltd | 発光素子材料およびそれを用いた発光素子並びに装置 |
AUPS065102A0 (en) | 2002-02-20 | 2002-03-14 | Unisearch Limited | Fluorous acetalation |
US7176227B2 (en) | 2002-09-11 | 2007-02-13 | Kureha Corporation | Amine compounds and use thereof |
KR101002822B1 (ko) | 2002-10-30 | 2010-12-21 | 스미또모 가가꾸 가부시키가이샤 | 고분자 화합물 및 이를 이용한 고분자 발광 소자 |
US7439253B2 (en) | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
US7271186B1 (en) | 2002-12-09 | 2007-09-18 | Northwestern University | Nanomolar β-lactamase inhibitors |
US20060194825A1 (en) | 2002-12-20 | 2006-08-31 | Migenix Corp. | Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto |
TW200418791A (en) | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
JP4233365B2 (ja) | 2003-03-25 | 2009-03-04 | 三井化学株式会社 | アザジオール錯体化合物、及び該化合物を用いる光記録媒体 |
US7842941B2 (en) | 2003-10-06 | 2010-11-30 | Sumitomo Chemical Company, Limited | Aromatic compound |
ES2288270T3 (es) | 2003-10-10 | 2008-01-01 | Pfizer Products Incorporated | 2h-(1,2,4)triazolo(4,3-a)pirazinas sustituidas como inhibidores de gsk-3. |
SI1689757T1 (sl) | 2003-11-12 | 2015-01-30 | Sino-Med International Alliance, Inc. | Heterociklične spojine boronske kisline |
TW200600494A (en) | 2004-03-08 | 2006-01-01 | Chugai Pharmaceutical Co Ltd | Bisphenyl compounds useful as vitamin d3 receptor agonists |
US20060019116A1 (en) | 2004-07-22 | 2006-01-26 | Eastman Kodak Company | White electroluminescent device with anthracene derivative host |
TW200618820A (en) | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
US20060178357A1 (en) | 2005-02-10 | 2006-08-10 | Buynak John D | Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases |
EP2987796B1 (en) * | 2005-02-16 | 2018-08-08 | Anacor Pharmaceuticals, Inc. | Halogen-substituted boronophthalides for the treatment of infections |
WO2006091771A2 (en) | 2005-02-22 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Preparation of rosuvastatin |
US9184428B2 (en) | 2005-03-15 | 2015-11-10 | Uchicago Argonne Llc | Non-aqueous electrolytes for lithium ion batteries |
US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
TW200734311A (en) | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
ES2373461T3 (es) | 2005-12-07 | 2012-02-03 | Basilea Pharmaceutica Ag | Antibióticos útiles de monobactama. |
ME02188B (me) | 2006-02-16 | 2016-02-20 | Anacor Pharmaceuticals Inc | Mali molekuli koji sadrže boron kao antiinflamatorni agensi |
EP2069347A2 (en) | 2006-09-27 | 2009-06-17 | Merck & Co., Inc. | Novel inhibitors of beta-lactamase |
NZ579375A (en) | 2007-03-23 | 2012-02-24 | Basilea Pharmaceutica Ag | Combination medicaments for treating bacterial infections |
GB0719366D0 (en) * | 2007-10-03 | 2007-11-14 | Smithkline Beecham Corp | Compounds |
US20100120715A1 (en) | 2007-11-13 | 2010-05-13 | Burns Christopher J | Beta-lactamase inhibitors |
CA2705389A1 (en) | 2007-11-13 | 2009-05-22 | Protez Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
PT2666774E (pt) | 2008-01-18 | 2015-04-13 | Merck Sharp & Dohme | Inibidores de beta-lactamase |
US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
WO2009140309A2 (en) | 2008-05-12 | 2009-11-19 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
CN102098918A (zh) | 2008-05-13 | 2011-06-15 | 帕纳德制药公司 | 用于治疗癌症和神经退行性疾病的生物活性化合物 |
BRPI0922566A2 (pt) | 2008-12-17 | 2017-03-28 | Anacor Pharmaceuticals Inc | polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença. |
US20120046242A1 (en) | 2008-12-24 | 2012-02-23 | Massachusetts Institute Of Technology | Molecular activators of the wnt/beta-catenin pathway |
WO2010097675A1 (en) | 2009-02-27 | 2010-09-02 | Dhanuka Laboratories Ltd. | An improved preparation process for cefpodoxime proxetil |
US20100292185A1 (en) | 2009-05-12 | 2010-11-18 | Burns Christopher J | Beta-lactamase inhibitors |
KR101460095B1 (ko) | 2009-06-08 | 2014-11-10 | 캘리포니아 캐피탈 에쿼티, 엘엘씨 | 트리아진 유도체와 이들의 치료적 용도 |
BR112012001987A2 (pt) | 2009-07-28 | 2015-09-01 | Anacor Pharmaceuticals Inc | Composto, combinação, formulação farmacêutica, uso de um composto, uma combinação ou um sal farmaceuticamente aceitável dos mesmos, e, métodos para tratar uma infecção bacteriana, para matar ou inibir o crescimento de uma bactéria, e para inibir uma beta-lactamase. |
EP2539348A4 (en) | 2010-02-26 | 2013-07-24 | Gary Igor Dmitrienko | CEPHALOSPORIN DERIVATIVES AS BETA LACTAMASE HEMMER AND COMPOSITIONS THEREFOR AND METHOD FOR THEIR USE |
AR080863A1 (es) | 2010-03-31 | 2012-05-16 | Millennium Pharm Inc | Derivados del acido1-amino-2-ciclopropiletilboronico, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer. |
US20110288063A1 (en) | 2010-05-19 | 2011-11-24 | Naeja Pharmaceutical Inc. | Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors |
JP5603487B2 (ja) | 2010-06-10 | 2014-10-08 | テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド | ヨウ化物の調製のためのプロセス |
US8680136B2 (en) | 2010-08-10 | 2014-03-25 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
EP2632927B1 (en) | 2010-10-26 | 2016-02-10 | Mars, Incorporated | Boronates as arginase inhibitors |
AU2011329486A1 (en) | 2010-11-18 | 2013-04-18 | Glaxo Group Limited | Compounds |
EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
EP2508506A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Preparation of sitagliptin intermediates |
US9012491B2 (en) | 2011-08-31 | 2015-04-21 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
WO2013053372A1 (en) | 2011-10-13 | 2013-04-18 | Therabor Pharmaceuticals | Boronic acid inhibitors of beta-lactamases |
WO2013056163A1 (en) | 2011-10-14 | 2013-04-18 | The Regents Of The University Of California | Beta-lactamase inhibitors |
US9688702B2 (en) | 2011-12-22 | 2017-06-27 | Ares Trading | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
WO2013104897A1 (en) | 2012-01-09 | 2013-07-18 | University of Tromsø | Therapeutic boron-containing compounds |
EP2615080A1 (en) | 2012-01-12 | 2013-07-17 | LEK Pharmaceuticals d.d. | Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof |
EP2814483A2 (en) | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
WO2014089365A1 (en) | 2012-12-07 | 2014-06-12 | Venatorx Pharmaceuticals, Inc | Beta-lactamase inhibitors |
CN104981239B (zh) | 2013-01-04 | 2019-01-04 | 莱姆派克斯制药公司 | 硼酸衍生物及其治疗用途 |
EA201591003A1 (ru) | 2013-01-04 | 2015-12-30 | Ремпекс Фармасьютикалз, Инк. | Производные бороновой кислоты и их терапевтическое применение |
US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US8999885B2 (en) | 2013-01-09 | 2015-04-07 | General Electric Company | Methods of activating charcoal resulting from biomass gasification |
ES2730013T3 (es) | 2013-01-10 | 2019-11-07 | Venatorx Pharmaceuticals Inc | Inhibidores de betalactamasa |
US9944658B2 (en) | 2013-03-14 | 2018-04-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
KR20150129034A (ko) | 2013-03-15 | 2015-11-18 | 인트렉손 코포레이션 | 붕소-함유 디아실하이드라진류 |
US9687497B1 (en) | 2014-05-05 | 2017-06-27 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
PT3140310T (pt) | 2014-05-05 | 2019-11-18 | Rempex Pharmaceuticals Inc | Síntese de sais de boronato e utilizações dos mesmos |
KR20170007448A (ko) | 2014-05-19 | 2017-01-18 | 렘펙스 파머수티클스 인코퍼레이티드 | 보론산 유도체 및 그의 치료적 용도 |
US9511142B2 (en) * | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
CN106687465B (zh) | 2014-06-11 | 2019-04-16 | 维纳拓尔斯制药公司 | β-内酰胺酶抑制剂 |
MX2016016666A (es) | 2014-07-01 | 2017-08-08 | Rempex Pharmaceuticals Inc | Derivados de acido boronico y usos terapeuticos de los mismos. |
WO2016065282A1 (en) | 2014-10-24 | 2016-04-28 | The Regents Of The University Of Michigan | Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels |
WO2016149393A1 (en) | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
CN107530364A (zh) | 2015-04-24 | 2018-01-02 | 莱姆派克斯制药公司 | 治疗细菌感染的方法 |
ES2894251T3 (es) | 2016-06-30 | 2022-02-14 | Qpex Biopharma Inc | Derivados de ácido borónico y usos terapéuticos de los mismos |
-
2011
- 2011-08-08 US US13/205,112 patent/US8680136B2/en active Active
- 2011-08-08 SG SG2013009378A patent/SG187757A1/en unknown
- 2011-08-08 EP EP11816882.2A patent/EP2603514B1/en active Active
- 2011-08-08 CA CA2807546A patent/CA2807546C/en active Active
- 2011-08-08 KR KR1020207006463A patent/KR102205755B1/ko active IP Right Grant
- 2011-08-08 MX MX2013001517A patent/MX348653B/es active IP Right Grant
- 2011-08-08 WO PCT/US2011/046957 patent/WO2012021455A1/en active Application Filing
- 2011-08-08 MY MYPI2013000386A patent/MY188960A/en unknown
- 2011-08-08 AU AU2011289615A patent/AU2011289615B2/en active Active
- 2011-08-08 KR KR1020137005086A patent/KR101987091B1/ko active IP Right Grant
- 2011-08-08 PL PL18183968T patent/PL3412676T3/pl unknown
- 2011-08-08 DK DK18183968.9T patent/DK3412676T3/da active
- 2011-08-08 ES ES18183968T patent/ES2789177T3/es active Active
- 2011-08-08 DK DK11816882.2T patent/DK2603514T3/en active
- 2011-08-08 LT LTEP18183968.9T patent/LT3412676T/lt unknown
- 2011-08-08 PT PT181839689T patent/PT3412676T/pt unknown
- 2011-08-08 PT PT11816882T patent/PT2603514T/pt unknown
- 2011-08-08 RU RU2013104951/04A patent/RU2599791C2/ru active
- 2011-08-08 NZ NZ607354A patent/NZ607354A/en unknown
- 2011-08-08 ES ES11816882.2T patent/ES2691468T3/es active Active
- 2011-08-08 HU HUE11816882A patent/HUE040086T2/hu unknown
- 2011-08-08 EP EP18183968.9A patent/EP3412676B1/en active Active
- 2011-08-08 HU HUE18183968A patent/HUE048859T2/hu unknown
- 2011-08-08 CN CN201180046975.2A patent/CN103180328B/zh active Active
- 2011-08-08 KR KR1020197015866A patent/KR102087313B1/ko active IP Right Grant
- 2011-08-08 EP EP20156442.4A patent/EP3666778B1/en active Active
- 2011-08-08 PL PL11816882T patent/PL2603514T3/pl unknown
- 2011-08-08 JP JP2013524151A patent/JP6266978B2/ja active Active
- 2011-08-08 BR BR112013003045-3A patent/BR112013003045B1/pt active IP Right Grant
- 2011-08-08 RS RS20200536A patent/RS60310B1/sr unknown
-
2013
- 2013-02-04 IL IL224564A patent/IL224564A/en active IP Right Review Request
- 2013-02-08 CL CL2013000399A patent/CL2013000399A1/es unknown
- 2013-02-25 CO CO13037941A patent/CO6680667A2/es unknown
- 2013-07-29 US US13/953,647 patent/US9296763B2/en active Active
-
2016
- 2016-02-03 US US15/015,002 patent/US9694025B2/en active Active
- 2016-12-01 JP JP2016234146A patent/JP6602742B2/ja active Active
-
2017
- 2017-06-15 US US15/624,473 patent/US10004758B2/en active Active
-
2018
- 2018-03-26 US US15/935,782 patent/US10183034B2/en active Active
- 2018-03-26 US US15/935,862 patent/US10172874B2/en active Active
- 2018-11-13 US US16/188,982 patent/US10639318B2/en active Active
-
2019
- 2019-03-28 HU HUS1900018C patent/HUS1900018I1/hu unknown
- 2019-03-28 NO NO2019014C patent/NO2019014I1/no unknown
- 2019-03-28 NO NO2019013C patent/NO2019013I1/no unknown
- 2019-03-28 HU HUS1900017C patent/HUS1900017I1/hu unknown
- 2019-10-09 JP JP2019185991A patent/JP6854861B2/ja active Active
-
2020
- 2020-03-24 US US16/828,859 patent/US11090319B2/en active Active
- 2020-05-08 CY CY20201100428T patent/CY1123208T1/el unknown
- 2020-05-08 HR HRP20200741TT patent/HRP20200741T1/hr unknown
- 2020-07-10 LT LTPA2020519C patent/LTC3412676I2/lt unknown
- 2020-07-10 CY CY2020019C patent/CY2020019I2/el unknown
- 2020-07-10 LT LTPA2020521C patent/LTC3412676DI2/lt unknown
- 2020-07-10 CY CY2020020C patent/CY2020020I2/el unknown
-
2021
- 2021-01-12 JP JP2021002699A patent/JP7227282B2/ja active Active
- 2021-07-16 US US17/378,248 patent/US11684629B2/en active Active
-
2023
- 2023-05-09 US US18/314,560 patent/US20230277571A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6680667A2 (es) | Derivados ester de ácido borónico cíclico y sus usos terapéuticos | |
MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
UY33776A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
MX2011009847A (es) | Agentes antihelminticos y su uso. | |
UA113651C2 (xx) | Макроциклічні пурини для лікування вірусних інфекцій | |
CO6491116A2 (es) | Derivados de 5-fluoropirimidinona | |
PE20121617A1 (es) | Derivados de oxazina como inhibidores de bace | |
UA109010C2 (en) | MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY | |
CO6741203A2 (es) | Derivados de biciclo[3,2,1]octilamida y sus usos | |
EA201390198A1 (ru) | Гетероциклическое соединение | |
UY32158A (es) | Derivados heterociclicos y metodos de uso de los mismos | |
PE20150627A1 (es) | Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso | |
UY32315A (es) | Compuestos de piperidina y usos de los mismo-596 | |
CO6491065A2 (es) | Formulación farmacéutica | |
UY34314A (es) | Derivados de anilina, su preparación y su aplicación terapéutica. | |
MX2020003495A (es) | Derivados de acido boronico y sintesis de los mismos. | |
UY32674A (es) | Derivados heterociclicos de la urea y sus metodos de empleo | |
TR201902057T4 (tr) | Tetrasiklin bileşikleri. | |
UY31016A1 (es) | Nuevos compuestos heterociclicos nitrogenados, su preparacion y su utilizacion como medicamentos antibacterianos | |
MX2011013869A (es) | Agentes antihelminticos y su uso. | |
ECSP11011053A (es) | [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos | |
UA109804C2 (xx) | 2-метоксипіридин-4-ільні похідні | |
BR112013000296A2 (pt) | agentes terapêuticos 976 | |
EA201591192A1 (ru) | Антибактериальные соединения | |
EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина |